Drawing for AFFILIN

USPTO serial 76396579

AFFILIN

Reviewed by CopyMark Law Group

Reg. 3379852Status 710
Filing date
Status date
Registration date
Feb 12, 2008
Examiner
KIM, YONG OH
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with AFFILIN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Richard E. Jenkins

RICHARD E. JENKINS JENKINS & WILSON, P.A.SUITE 1200 UNIVERSITY TOWER3100 TOWER BOULEVARDDURHAM, NC 27707

Goods and services

ClassDescriptionStatusFirst use
001chemical preparations, namely, artificial binding molecules in the nature of proteins and peptides for use in the environmental industry, biotechnological industry, food industry, cosmetic industry, and gmp production; chemical substances, namely biologically active proteins and peptides with antibody-like binding activities for use in the environmental industry, biotechnological industry, food industry, cosmetic industry, and gmp production; diagnostic reagents and analytical reagents for scientific research use or for use in the biotechnological industry, pharmaceutical industry, food industry, cosmetic industry, and gmp production or for laboratory use or for purification or depletion of chemical or biological substancesSECTION 8 - CANCELLED—
005PHARMACEUTICAL PREPARATIONS FOR USE IN THE TREATMENT OF CYSTIC FIBROSIS, PSYCHOSOMATIC DISEASES, DEPRESSION, EPILEPSY, ENDOCRINOLOGIC DISORDERS, CIRRHOSES, DISEASES ASSOCIATED WITH HORMONAL DISTURBANCES, AUTOIMMUNE DISEASES, EYE DISEASES, OBESITY, METABOLIC DISEASES, STROKE, INFECTIOUS DISEASES, CANCER, DEGENERATIVE DISEASES, NEURODEGENERATIVE DISEASES, ASTHMATIC DISEASES, DERMATOLOGIC DISEASES, MUSCULOSKELETAL DISEASES, PERIODONTOSIS, DENTAL DISEASES, DIABETES, CARDIOVASCULAR DISEASES, INFLAMMATORY DISEASES, HEMATOLOGIC DISEASES, UROLOGIC DISEASES OR ERECTILE DYSFUNCTIONS, PSYCHOLOGICAL DISEASES, BRONCHOLYTIC DISEASES, PULMONARY DISEASES, DERMATOLOGICAL DISEASES, LIPID METABOLISM DISORDERS, MIGRAINE, DEMENTIA, RHEUMATIC DISORDERS, GASTRIC AND INTESTINAL DISEASES, ENZYME DEFICIENCY AND TRANSPORT PROTEINS DISORDERS, ANALEPTIC DISEASES, ANORETIC DISEASES, BLOOD DISEASES, ALLERGIC DISEASES, ANEMIC DISEASES, GERIATRIC DISEASES, COLD AND FLU, HEPATIC DISEASES, IMMUNOLOGICAL DISEASES, CARDIAC DISEASES, SKELETAL AND MUSCLE DISEASES, OSTEOPOROSIS, OTOLOGICAL DISEASES, MOUTH AND PHARYNGEAL DISEASES, ASTHMATIC DISEASES, BILE-DUCT DISORDERS, AND ARTERIOSCLEROSIS; VETERINARY PREPARATIONS FOR USE IN THE TREATMENT OF CYSTIC FIBROSIS, PSYCHOSOMATIC DISEASES, DEPRESSION, EPILEPSY, ENDOCRINOLOGIC DISORDERS, CIRRHOSES, DISEASES ASSOCIATED WITH HORMONAL DISTURBANCES, AUTOIMMUNE DISEASES, EYE DISEASES, OBESITY, METABOLIC DISEASES, STROKE, INFECTIOUS DISEASES, CANCER, DEGENERATIVE DISEASES, NEURODEGENERATIVE DISEASES, ASTHMATIC DISEASES, DERMATOLOGIC DISEASES, MUSCULOSKELETAL DISEASES, PERIODONTOSIS, DENTAL DISEASES, DIABETES, CARDIOVASCULAR DISEASES, INFLAMMATORY DISEASES, HEMATOLOGIC DISEASES, UROLOGIC DISEASES OR ERECTILE DYSFUNCTIONS, PSYCHOLOGICAL DISEASES, BRONCHOLYTIC DISEASES, PULMONARY DISEASES, DERMATOLOGIC DISEASES, LIPID METABOLISM DISORDERS, MIGRAINE, DEMENTIA, RHEUMATIC DISORDERS, GASTRIC AND INTESTINAL DISEASES, ENZYME DEFICIENY AND TRANSPORT PROTEINS DISORDERS, ANALEPTIC DISEASES, ANORETIC DISEASES, BLOOD DISEASES, ALLERGIC DISEASES, ANEMIC DISEASES, GERIATRIC DISEASES, COLD AND FLU, HEPATIC DISEASES, IMMUNOLOGICAL DISEASES, CARDIAC DISEASES, SKELETAL AND MUSCLE DISEASES, OSTEOPOROSIS, OTOLOGICAL DISEASES, MOUTH AND PHARYNGEAL DISEASES, ASTHMATIC DISEASES, BILE-DUCT DISORDERS, AND ARTERIOSCLEROSIS; MEDICAL, DIAGNOSTIC, CHEMICAL AND ANALYTIC REAGENTS FOR USE IN THE TREATMENT OF CYSTIC FIBROSIS, PSYCHOSOMATIC DISEASES, DEPRESSION, EPILEPSY, ENDOCRINOLOGIC DISORDERS, CIRRHOSES, DISEASES ASSOCIATED WITH HORMONAL DISTURBANCES, AUTOIMMUNE DISEASES, EYE DISEASES, OBESITY, METABOLIC DISEASES, STROKE, INFECTIOUS DISEASES, CANCER, DEGENERATIVE DISEASES, NEURODEGENERATIVE DISEASES, ASTHMATIC DISEASES, DERMATOLOGIC DISEASES, MUSCULOSKELETAL DISEASES, PERIODONTOSIS, DENTAL DISEASES, DIABETES, CARDIOVASCULAR DISEASES, INFLAMMATORY DISEASES, HEMATOLOGIC DISEASES, UROLOGIC DISEASES OR ERECTILE DYSFUNCTIONS, PSYCHOLOGICAL DISEASES, BRONCHOLYTIC DISEASES, PULMONARY DISEASES, DERMATOLOGIC DISEASES, LIPID METABOLISM DISORDERS, MIGRAINE, DEMENTIA, RHEUMATIC DISORDERS, GASTRIC AND INTESTINAL DISEASES, ENZYME DEFICIENCY AND TRANSPORT PROTEINS DISORDERS, ANALEPTIC DISEASES, ANORETIC DISEASES, BLOOD DISEASES, ALLERGIC DISEASES, ANEMIC DISEASES, GERIATRIC DISEASES, COLD AND FLU, HEPATIC DISEASES, IMMUNOLOGICAL DISEASES, CARDIAC DISEASES, SKELETAL AND MUSCLE DISEASES, OSTEOPOROSIS, OTOLOGICAL DISEASES, MOUTH AND PHARYNGEAL DISEASES, ASTHMATIC DISEASES, BILE-DUCT DISORDERS, AND ARTERIOSCLEROSIS; AND DIAGNOSTIC PREPARATIONS FOR CLINICAL AND MEDICAL LABORATORY USESECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 19, 2014C8..CANCELLED SEC. 8 (6-YR)—
Feb 12, 2008R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jan 9, 2008OP.TOPPOSITION TERMINATED NO. 999999—
Jan 8, 2008OP.DOPPOSITION DISMISSED NO. 999999—
Jun 5, 2007DOCKASSIGNED TO EXAMINER—
Dec 5, 2005OP.IOPPOSITION INSTITUTED NO. 999999—
Jun 30, 2005ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Jun 7, 2005PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 18, 2005NPUBNOTICE OF PUBLICATION—
Feb 16, 2005PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Feb 11, 2005ALIEASSIGNED TO LIE—
Jan 24, 2005ALIEASSIGNED TO LIE—
Dec 21, 2004CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 19, 2004CNFRFINAL REFUSAL MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
May 14, 2004CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 14, 2004MAILPAPER RECEIVED—
Nov 13, 2003CNSIINQUIRY AS TO SUSPENSION MAILED—
Oct 23, 2003CFITCASE FILE IN TICRS—
Apr 2, 2003CNSLLETTER OF SUSPENSION MAILED—
Feb 19, 2003CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 19, 2003MAILPAPER RECEIVED—
Aug 26, 2002CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 8, 2002DOCKASSIGNED TO EXAMINER—

Frequently asked questions

Related guidance